A New Era in Influenza: Differential Diagnosis & Antiviral Selection in the Complex COVID-19 Landscape
Webinar/Online
Thursday, November 11, 2021 at 7:00pm CT - 8:00pm CT
This event has ended.
Info
Speaker(s)
Ruth Carrico, PhD, DNP, APRN, CIC, FSHEA, FNAP
Credits Offered
This event offers
1.0 CE credit
to attendees
(0.4 pharmacology)
.
Accreditation Info:
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Paradigm Medical Communications, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.4 hours) of pharmacology)..
Additional Information
With a growing national shortage of primary care physicians, today’s complex and dynamic healthcare environment increasingly places nurse practitioners (NPs) and PAs as front-and-center clinical managers of infectious diseases like influenza and the global COVID-19 (SARS-CoV-2) pandemic makes these frontline clinicians more important than ever before. Influenza and SARS-CoV-2 viruses can cause similar symptoms, making differential diagnosis difficult and even more confounding to clinicians, patients can be coinfected with both SARS-CoV-2 and influenza viruses simultaneously. The global impact of COVID-19 has resulted in rapid, ongoing changes to influenza practice guidelines. This educational initiative will provide a concise, case-based, expert-led review of the latest clinical practices and best available evidence for effective influenza management, targeted to the unique needs of NPs and PAs.
Learning Objectives
After completing this activity, the participant should be better able to:
- Recognize patients who would most benefit from antiviral therapy based on risk of influenza-related complications, in accordance with evolving recommendations in the COVID-19 era.
- Distinguish influenza from other viral infections in patients based on signs, symptoms, and test results in the COVID-19 era
- Develop individualized antiviral treatment plans that are safe and effective for patients with, or at risk of, influenza and/or possible co-infections in the rapidly evolving COVID-19 era.